KRAS and neoplasm: Various metabolic factors such as hypoxia (78), immunological components including suppressive immune cells, cytokines, and MHC-II expression (79), as well as tumor-intrinsic drivers such as oncogenic mutations (e.g., KRAS, TP53, and BRAF) and aberrant signaling pathways (80), collectively influence the infiltration of CD4+ T cells.